QPPV.COM KNOWLEDGE ASSESSMENT

Natalizumab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance

Test your understanding of the concepts covered by Natalizumab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which example best illustrates why disease activity and treatment effect must be separated in natalizumab cases?

A new neurological deficit could represent relapse, pseudo-relapse, infection, treatment-associated disease or an unrelated neurological disorder Any symptom occurring during treatment is necessarily caused by the product Multiple-sclerosis relapse can be excluded whenever the patient has received a recent dose A disease-related explanation is valid only when no laboratory test is available

Question 2 of 10 Which combination of information is most important when evaluating suspected progressive multifocal leukoencephalopathy in a natalizumab case?

Patient occupation, dietary history and previous vaccination dates JCV status or index where used clinically, prior immunosuppression, treatment duration, neurological evolution, MRI findings and relevant CSF testing Only the date of the most recent infusion and the reported preferred term The presence or absence of an administration-site reaction

Question 3 of 10 What does a high-quality follow-up process measure according to the article?

The number of follow-up requests sent, regardless of response Whether relevant information was obtained, evaluated and incorporated into the case assessment Whether every reporter was contacted at least three times Whether all cases received the same standardized questions

Question 4 of 10 Why should JCV status, prior immunosuppression and treatment duration be retained as structured or readily retrievable case variables?

They replace the need for clinical assessment of suspected PML They are relevant exposure and susceptibility strata that can change the interpretation of serious neurological events They are required only for product quality complaints They determine whether every infection is expected and non-serious

Question 5 of 10 Why is recording the exact presentation, route, administration date and batch important in natalizumab case handling?

It is relevant to chronology, administration assessment, product traceability and potential quality investigations It allows causality to be assigned without clinical information It is needed only when the event is mild It eliminates the need to document concomitant medicines

Question 6 of 10 Which case narrative best supports a reliable causality assessment?

A preferred term, a statement that the event is known, and no further clinical details A complete chronology linking treatment indication, exact exposure, concomitant therapies, onset, objective findings, interventions, outcome and competing explanations A report containing only the patient's age and the final causality category A narrative focused solely on the mechanism of action without patient-level findings

Question 7 of 10 Why can interruption of natalizumab not automatically be treated as complete dechallenge?

Because the drug has no measurable pharmacological effect after administration Because biological and pharmacodynamic effects may persist after dosing has stopped Because dechallenge applies only to small-molecule medicines Because any event after interruption must be attributed to the underlying disease

Question 8 of 10 Which signal-detection strategy is most consistent with the article's recommendations?

Pool all natalizumab cases because the active substance is the same Analyse preferred-term counts without considering disease severity or exposure duration Stratify by clinically meaningful factors such as indication, treatment phase, duration, treatment line, age, prior therapy and presentation Exclude cases with incomplete information from all exploratory analyses

Question 9 of 10 Which follow-up would be most useful for a suspected natalizumab infusion or hypersensitivity reaction?

Route, dose, administration rate, timing, vital signs, clinical phenotype, treatment, observation period, batch and any repeat exposure Only the patient's JCV antibody index Only whether the event was entered using an administration-related preferred term The patient's long-term multiple-sclerosis disability score without event chronology

Question 10 of 10 What is the principal regulatory value of preserving source-to-decision traceability in natalizumab pharmacovigilance?

It demonstrates how source information was evaluated, how uncertainty was handled and how conclusions or actions were reached It ensures that every case receives the same causality conclusion It removes the need for medical review when the source is complete It permits aggregate conclusions without defining the exposure denominator

QPPV.com

Natalizumab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance

Cookie Settings